Marco Meglio

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

The findings suggest that plasma exchange has the potential to offer patients with Alzheimer disease a new modality of treatment, though additional studies are needed to further investigate the current areas of uncertainty.

Results from the ATLAS Posterior PMA trial demonstrated that physicians can now address the more difficult posterior circulation aneurysms, offering hope for better outcomes in that patient population.

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

NeuroPace’s FDA-approved neurostimulation device helped 35% of patients with epilepsy achieve ≥90% reduction in seizure frequency, with 18% of patients reporting seizure freedom at last follow-up.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

The findings indicate that the use of a MS severity score (Ped-MSSS) model may provide an alternative to EDSS scoring, which has been shown to be lower in pediatric disease, in clinical assessment of disease severity and disability accrual.

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research discussed the recent phase 2 JUNIPER upper limb spasticity trial of daxibotulinumtoxinA for injection.

Join NeurologyLive and the Women Neurologist Group on Twitter to discuss the importance of mental health and wellness in neurologic disorders.

The Patient Controller app will be made available in the coming weeks, according to designer Abbott.

The study authors noted that clinicians should consider the data when recommending endovascular treatment for older adults.

In part 2 of this interview, the vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases portfolio discusses future trials with ticagrelor and when they anticipate a possible FDA approval.

The regulatory agency has set prescription drug user fee act action date of April 3, 2021, for the Acadia Pharmaceuticals product.

The treatment, marketed as Xywav, becomes the first treatment indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in 15 years.

As of February of this year, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.

The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases portfolio discussed the findings of the THALES trial, and how ticagrelor stands alone among stroke treatments.

The FDA-approved medication showed a robust ability to decrease hours spent “on” with troublesome dyskinesia in patients with Parkinson disease.

REN may offer a novel alternative for current pharmacological and non-pharmacological treatments in chronic migraine that combines efficient treatment with minimal adverse effects.

The Clinigen Group’s ALS treatment is currently being investigated in a phase 2 trial that is expected to conclude in September 2021.

In addition to showing significant and clinically meaningful reduction in acute ischemic stroke and transient ischemic attack, ticagrelor showed a consistent safety profile to what has been observed in previous trials.

The 18F-PI-2620 radiotracer’s positive effect on diagnosing and differentiating patients with suspected progressive supranuclear palsy leaves questions about its potential as a PSP progression biomarker.

The findings are particularly relevant for prehospital stroke awareness and improvement of in-hospital acute stroke protocols.

Low-risk, digital video game interventions could represent a clinically valuable approach to improving processing speed in adults with multiple sclerosis.